Literature DB >> 24900617

Inhibition of CK2: An Attractive Therapeutic Target for Cancer Treatment.

Ahmed F Abdel-Magid1.   

Abstract

Year:  2013        PMID： 24900617      PMCID： PMC4027548          DOI： 10.1021/ml400410p

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.345


× No keyword cloud information.
  3 in total

Review 1.  Kinase CK2 inhibition: an update.

Authors:  G Cozza; L A Pinna; S Moro
Journal:  Curr Med Chem       Date:  2013       Impact factor: 4.530

Review 2.  Protein kinase CK2 inhibitors: a patent review.

Authors:  Giorgio Cozza; Lorenzo A Pinna; Stefano Moro
Journal:  Expert Opin Ther Pat       Date:  2012-09       Impact factor: 6.674

3.  Druggability of the CK2 inhibitor CX-4945 as an anticancer drug and beyond.

Authors:  Jiyeon Kim; Seong Hwan Kim
Journal:  Arch Pharm Res       Date:  2012-08       Impact factor: 4.946
  3 in total
  3 in total

1.  Identification and Biological Evaluation of CK2 Allosteric Fragments through Structure-Based Virtual Screening.

Authors:  Chunqiong Li; Xuewen Zhang; Na Zhang; Yue Zhou; Guohui Sun; Lijiao Zhao; Rugang Zhong
Journal:  Molecules       Date:  2020-01-06       Impact factor: 4.411

2.  Preclinical efficacy of CIGB-300, an anti-CK2 peptide, on breast cancer metastasic colonization.

Authors:  Maria F Gottardo; Carla S Capobianco; Johanna E Sidabra; Juan Garona; Yasser Perera; Silvio E Perea; Daniel F Alonso; Hernan G Farina
Journal:  Sci Rep       Date:  2020-09-07       Impact factor: 4.379

3.  A meta-analysis and bioinformatics exploration of the diagnostic value and molecular mechanism of miR-193a-5p in lung cancer.

Authors:  Zu-Cheng Xie; Rui-Xue Tang; Xiang Gao; Qiong-Ni Xie; Jia-Ying Lin; Gang Chen; Zu-Yun Li
Journal:  Oncol Lett       Date:  2018-07-19       Impact factor: 2.967
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.